ANNA

Anna Biosciences’ first initiative, the Syntem Platform, is developing proprietary molecules to create synthetic immunity. Our initial efforts are focused on virology, immuno-oncology, and neurodegenerative diseases. The platform’s multi-specific molecules first target and flag the pathology, and then elicit an immune reaction that targets the virus or disease.

The Syntem Platform’s proprietary molecules and treatments have the potential to yield numerous advantages including:

— Targeted therapies with minimal side effects
— Ease of administration to patients
— Ease of production
— Lower overall treatment costs

The first application of the platform is as a therapy which activates immune cells that can recognize and attack cancers.

The Syntem Platform relies on proprietary molecules that work by flagging the pathology for recognition by the patient’s immune system by using a patented “chemical engagement” technology that enforces immune cell engagement with the targeted diseased cells or viral pathogen.

The Syntem platform uses proprietary new molecular entities we call covalent immune recruiters (CIR). In Syntem’s therapies, the CIRs irreversibly bind with immune machinery like serum antibodies, forcing proximity with disease target receptors (Target Protein). This enables both high precision recognition of the receptor and high precision targeting of disease.